David Amaral is distinguished professor of psychiatry and behavioral sciences at the University of California, Davis MIND Institute.
David Amaral
Director
Autism BrainNet
From this contributor
‘Prototypical autism’ research is likely a dead end
Efforts to define “frank” or “classic” forms of the condition build on several assumptions that the science has not yet borne out.
‘Prototypical autism’ research is likely a dead end
By
Deborah Fein, David Amaral, Einat Waizbard-Bartov
25 January 2024 | 8 min read
Questions for Amaral, Halladay: Boosting brainpower
A new network of brain banks aims to collect and disburse tissue donations to U.S. autism researchers.
Questions for Amaral, Halladay: Boosting brainpower
By
Katie Moisse
15 December 2015 | 6 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read